Lates News

Every AI express, Guojin Securities released a research report on March 12, giving Xintai (002294.SZ) a "buy" rating. The reasons for the rating mainly include: 1) Leading domestic heart and kidney metabolic syndrome, innovative transformation accelerating realization; 2) Nephrology, metabolism and orthopedic pipeline in full bloom, building a closed-loop chronic disease product; 3) Actively promoting the Hong Kong listing process, intending to empower innovative drug R&D through the construction of an "A+H" dual-capital platform. (Daily Economic News)